FLT3 and acute myeloid leukemia: Thirty patients with ND FLT3mut AML and a median age of 71 (73% with FLT3-ITD, 27% with FLT3-TKD) received AZA + VEN + GILT, with CRc rates of 96% and a median OS which was not reached at median follow-up 19 months (18-month OS 72%, 18-month relapse-free survival 71%, Fig. 2) [47].